STOCK TITAN

LianBio - LIAN STOCK NEWS

Welcome to our dedicated news page for LianBio (Ticker: LIAN), a resource for investors and traders seeking the latest updates and insights on LianBio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LianBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LianBio's position in the market.

Rhea-AI Summary
LianBio has entered into an agreement with Bristol Myers Squibb (BMS) for the exclusive rights to develop and commercialize mavacamten in several Asian markets. LianBio will receive $350 million upfront and be released from remaining milestone payments. The China National Medical Products Administration has accepted a New Drug Application for mavacamten. LianBio's Board of Directors has initiated a strategic review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
117.27%
Tags
none
-
Rhea-AI Summary
LianBio presents positive data on mavacamten in Chinese oHCM patients at ESC 2023 and JAMA Cardiology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
-
Rhea-AI Summary
LianBio reports financial results for Q2 2023 and provides updates on clinical development milestones. Mavacamten NDA under priority review in China. Positive results from EXPLORER-CN trial. Cash balance of $267.3 million. Anticipated milestones for mavacamten, TP-03, infigratinib, and BBP-398.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
Rhea-AI Summary
LianBio has announced the dosing of the first patient in its Phase 1 clinical trial of BBP-398, an SHP2 inhibitor, in combination with AstraZeneca's osimertinib for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. SHP2 overactivity is a critical contributor to cancer and resistance to targeted therapies. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of the combination therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.94%
Tags
-
Rhea-AI Summary
Tarsus Pharmaceuticals received FDA approval for XDEMVY™ (lotlilaner ophthalmic solution) 0.25% to treat Demodex blepharitis, marking the first FDA-approved treatment targeting Demodex mites. LianBio, the partner of Tarsus, is conducting a Phase 3 trial in China and expects to report results in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
-
Rhea-AI Summary
LianBio announces clinical supply agreement with AstraZeneca in China to evaluate BBP-398 in combination with osimertinib for the treatment of NSCLC patients with EGFR mutations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.88%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
LianBio

Nasdaq:LIAN

LIAN Rankings

LIAN Stock Data

34.47M
25.38M
5.91%
78.99%
0.35%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Princeton

About LIAN

lianbio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in china and major asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. lianbio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.